Enavate Sciences GP, LLC — 13F Holdings & Portfolio
CIK 1953107 · latest 13F-HR filed 2026-05-15
Enavate Sciences GP, LLC manages $351.5M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are SION (28.26%), IMNM (22.48%), ZBIO (21.80%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 0, added to 0, and trimmed 5.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$351.5M
Long-equity book
7
Distinct positions
2026-03-31
Filed 2026-05-15
+0 / −0 / ↑0 / ↓5
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Trims
- ZENAS BIOPHARMA INC-$65.7M -46.2%
- UPSTREAM BIO INC-$44.6M -66.9%
- IMMUNOME INC-$23.4M -22.8%
- BRIDGEBIO ONCOLOGY THERAPEUT-$9.4M -28.5%
- CAMP4 THERAPEUTICS CORP-$8.9M -48.1%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SIONNA THERAPEUTICS INC | SION | 829401108 | $99.3M | 28.26% | 2,478,030 | SH |
| 2 | IMMUNOME INC | IMNM | 45257U108 | $79.0M | 22.48% | 3,613,799 | SH |
| 3 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $76.6M | 21.80% | 3,919,159 | SH |
| 4 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $41.2M | 11.72% | 7,788,150 | SH |
| 5 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $23.5M | 6.69% | 2,626,946 | SH |
| 6 | UPSTREAM BIO INC | UPB | 91678A107 | $22.1M | 6.30% | 2,459,703 | SH |
| 7 | CAMP4 THERAPEUTICS CORP | CAMP | 13463J101 | $9.7M | 2.75% | 2,190,920 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $351.5M | 7 | 0001953107-26-000008 |
| 2025-12-31 | 2026-02-17 | $506.8M | 7 | 0001953107-26-000003 |
| 2025-09-30 | 2025-11-14 | $327.5M | 7 | 0001953107-25-000014 |